Guide
Tirzepatide Plateau: Why Weight Loss Stalls and What the Data Says
A plateau is the expected shape of the curve rather than a failure. In SURMOUNT-1 the rate of loss slowed markedly after roughly a year and the trial ended at a plateau,
A plateau is the expected shape of the curve rather than a failure. In SURMOUNT-1 the rate of loss slowed markedly after roughly a year and the trial ended at a plateau, not a decline. A stall is a reason for a clinical conversation, not for a dose change you make yourself.
Is a plateau a failure?
No. Every published GLP-1 weight trial shows the same shape: rapid loss after reaching a maintenance dose, then a flattening. SURMOUNT-1 ended at 72 weeks with the curve already flat, which is what a new equilibrium looks like rather than what a drug wearing off looks like.
| Trial | Drug | Endpoint | Curve at the end |
|---|---|---|---|
| SURMOUNT-1 | Tirzepatide | 22.5% at 72 weeks | Flattening |
| SURMOUNT-5 | Tirzepatide vs semaglutide | 20.2% vs 13.7% | Flattening in both arms |
| STEP-1 | Semaglutide | 14.9% at 68 weeks | Flattening |
We are not going to publish a “break the plateau” protocol. Dose changes, drug switches and holds are clinical decisions that depend on your history, your tolerability and what else you take.
What we can say is that a stall is common, expected in the data, and a reason to talk to a prescriber rather than to self-adjust or to buy a higher-dose vial from a cheaper source.
What does a plateau do to the cost question?
It changes it entirely. If treatment is indefinite rather than a 72-week course, the figure that matters is the annual maintenance cost, not the entry price.
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $215 | $195 | $190 | $186 | $2,232 |
| Microdose | $189 | $159 | $150 | $147 | $1,764 |
| Sublingual ODT | $229 | $219 | $205 | $199 | $2,388 |
Flat at every covered dose within each protocol, read on the provider’s own plan pages. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.
On a flat plan the maintenance year costs the same as the first. On a tiered plan it is the most expensive year, because a plateau means you are sitting at the top of the ladder permanently.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
What questions are worth asking at a plateau review?
- Am I at a maintenance dose in the approved range, or still mid-titration?
- What does the current dose cost me for another twelve months?
- Is the plateau at a weight my prescriber considers a reasonable endpoint?
- What happens to weight if treatment stops? The published data on discontinuation is unambiguous and worth reading before deciding.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
Why has my tirzepatide weight loss stalled?
A plateau is the expected shape in every published GLP-1 trial: rapid loss after reaching a maintenance dose, then flattening. SURMOUNT-1 ended at a plateau rather than a decline.
Does a plateau mean the drug stopped working?
Not in the trial data — the curve flattens rather than reverses. A stall is a reason for a clinical review, not a self-made dose change.
How does a plateau change the cost?
It makes annual maintenance cost the number that matters rather than the entry price, because treatment is indefinite rather than a fixed course.
Related on this site
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Ro Body vs Hims & HersComparisons
- Hims & Hers vs Henry MedsComparisons
- Brand-Name vs Compounded TirzepatidePillar / Money
- Tirzepatide for Type 2 DiabetesResearch
- Tirzepatide and Sleep Apnea: Evidence and FDA StatusJournal
- Compounded vs Brand Tirzepatide: Legal and Evidence DifferencesJournal
- PlushCare Tirzepatide ReviewProviders
Related coverage
GLP-1 Tirzepatide Rank. “Tirzepatide Plateau: Why Weight Loss Stalls and What the Data Says.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/tirzepatide-plateau-stalled-weight-loss-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.